Home » Stocks » STIM

Neuronetics, Inc. (STIM)

Stock Price: $16.68 USD -0.27 (-1.59%)
Updated Jan 20, 2021 2:18 PM EST - Market open
Market Cap 321.63M
Revenue (ttm) 51.02M
Net Income (ttm) -31.35M
Shares Out 18.89M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $16.68
Previous Close $16.95
Change ($) -0.27
Change (%) -1.59%
Day's Open 17.24
Day's Range 15.34 - 17.24
Day's Volume 361,412
52-Week Range 1.28 - 17.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

Zacks Investment Research - 1 week ago

Neuronetics (STIM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 1 week ago

MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

GlobeNewsWire - 1 month ago

Amendment provides Neuronetics with available and flexible funding options through 2022 Amendment provides Neuronetics with available and flexible funding options through 2022

GlobeNewsWire - 1 month ago

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

Seeking Alpha - 1 month ago

Neuronetics makes a device that stimulates the brain, showing efficacy in MDD patients. Despite being in business for nearly two decades, this is a small company and a depressed stock.

GlobeNewsWire - 1 month ago

TouchStar theta burst protocol leverages NeuroStar® Advanced Therapy's patented Contact Sensing technology to help ensure the optimum prescribed treatment dose to patients TouchStar theta burs...

GlobeNewsWire - 2 months ago

MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

Seeking Alpha - 2 months ago

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Neuronetics (STIM) delivered earnings and revenue surprises of 41.94% and 11.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

Zacks Investment Research - 2 months ago

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that imp...

Benzinga - 3 months ago

The following originally appeared on CapitalWatch An increasing number of Americans becoming increasingly anxious or depressed or worse. To wit, there were more than 72,000 fatal overdoses in ...

Other stocks mentioned: CMPS, MMEDF
GlobeNewsWire - 3 months ago

MALVERN, Pa., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psych...

GlobeNewsWire - 3 months ago

Participating practices educate patients with depression about non-drug treatment options like NeuroStar Advanced Therapy Participating practices educate patients with depression about non-dru...

GlobeNewsWire - 3 months ago

The market leader in transcranial magnetic stimulation therapy applauds leading NeuroStar® Advanced Therapy provider The market leader in transcranial magnetic stimulation therapy applauds lea...

GlobeNewsWire - 3 months ago

Neuronetics will share clinical data on its NeuroStar® Advanced Therapy treatment, including a bipolar depression pilot study, outcomes registry, and DASH protocol Neuronetics will share clini...

Seeking Alpha - 5 months ago

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

MALVERN, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that i...

Zacks Investment Research - 5 months ago

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

MALVERN, Pa., July 17, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psy...

Zacks Investment Research - 6 months ago

Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

MALVERN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psy...

GlobeNewsWire - 6 months ago

MALVERN, Pa., June 26, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that i...

Seeking Alpha - 8 months ago

Neuronetics, Inc. (STIM) Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

MALVERN, Pa., April 08, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that ...

GlobeNewsWire - 9 months ago

MALVERN, Pa., April 08, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that ...

Zacks Investment Research - 9 months ago

Bet on these top--ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: DENN, FLDM, OCGN, RCKY
GlobeNewsWire - 9 months ago

Company acknowledged on Top 10 List by MedTech Outlook Magazine

GlobeNewsWire - 10 months ago

An increasing number of patients and providers are turning to the transcranial magnetic stimulation (TMS) market leader as a proven, non-drug treatment option for depression An increasing numb...

GlobeNewsWire - 10 months ago

NeuroStar, developed by Neuronetics, Inc., is the first transcranial magnetic stimulation (TMS) device to receive Breakthrough Device Designation for bipolar depression NeuroStar, developed by...

GlobeNewsWire - 10 months ago

MALVERN, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that ...

Seeking Alpha - 10 months ago

Neuronetics' (STIM) CEO Chris Thatcher on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Neuronetics (STIM) delivered earnings and revenue surprises of 8.89% and 2.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 11 months ago

Weighing In On Neuronetics

GlobeNewsWire - 11 months ago

MALVERN, Pa., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that im...

GlobeNewsWire - 1 year ago

MALVERN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that im...

Seeking Alpha - 1 year ago

Neuronetics, Inc. (STIM) CEO Chris Thatcher on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

MALVERN, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that i...

Seeking Alpha - 1 year ago

Neuronetics, Inc.'s (STIM) CEO Chris Thatcher on Q2 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

Along with issues around ongoing talcum and opioid exposure, some rivals may have been winning at the company’s expense.

Other stocks mentioned: BSX, ISRG, PEN, SYK
Investors Business Daily - 1 year ago

JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology.

Other stocks mentioned: BSX, ISRG, PEN
Seeking Alpha - 1 year ago

Neuronetics, Inc. (STIM) CEO Chris Thatcher on Q1 2019 Results - Earnings Call Transcript

About STIM

Neuronetics, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the b... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 28, 2018
Stock Exchange
NASDAQ
Ticker Symbol
STIM
Full Company Profile

Financial Performance

In 2019, Neuronetics's revenue was $62.66 million, an increase of 18.72% compared to the previous year's $52.78 million. Losses were -$29.04 million, 20.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Neuronetics stock is "Buy." The 12-month stock price forecast is 14.25, which is a decrease of -14.57% from the latest price.

Price Target
$14.25
(-14.57% downside)
Analyst Consensus: Buy